Yuka Harada

Yuka Harada

Auto-generated profile, based on publicly available information

Yuka Harada

Department of Clinical Laboratory, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
YAYasushige Aoyagi
Yasushige Aoyagi
YHYoshihiro Hayashi
Yoshihiro Hayashi
YHYuka Harada
Yuka Harada
KCKwangmin Choi
Kwangmin Choi
NMNatsumi Matsunuma
Natsumi Matsunuma
HHHironori Harada
Hironori Harada
Ineffective hematopoiesis is a fundamental process leading to the pathogenesis of myelodysplastic syndromes (MDS). However, the pathobiological mediators of ineffective hematopoiesis in MDS remain unclear. Here, we demonstrated that overwhelming mitochondrial fragmentation in mutant hematopoietic stem cells and progenitors (HSC/P) triggers ineffective hematopoiesis in MDS. Mouse modeling of CBL exon deletion with RUNX1 mutants, previously unreported comutations in patients with MDS, recapitulated not only clinically relevant MDS phenotypes but also a distinct MDS-related gene signature. Mechanistically, dynamin-related protein 1 (DRP1)–dependent excessive mitochondrial fragmentation in HSC/Ps led to excessive reactive oxygen species production, induced inflammatory signaling activation, and promoted subsequent dysplasia formation and impairment of granulopoiesis. Mitochondrial fragmentation was generally observed in patients with MDS. Pharmacologic inhibition of DRP1 attenuated mitochondrial fragmentation and rescued ineffective hematopoiesis phenotypes in mice with MDS. These findings provide mechanistic insights into ineffective hematopoiesis and indicate that dysregulated mitochondrial dynamics could be a therapeutic target for bone marrow failure in MDS. Significance: We demonstrated that excessive mitochondrial fragmentation is a fundamental pathobiological phenomenon that could trigger dysplasia formation and ineffective hematopoiesis in MDS. Our findings provide mechanistic insights into ineffective hematopoiesis and suggest dysregulated mitochondrial dynamics as a therapeutic target for treating MDS. This article is highlighted in the In This Issue feature, p. 1

30 March 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
YHYoshihiro Hayashi
Yoshihiro Hayashi
YHYuka Harada
Yuka Harada
HHHironori Harada
Hironori Harada

5 August 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
YNYuho Najima
Yuho Najima
DSDaichi Sadato
Daichi Sadato
YHYuka Harada
Yuka Harada
KOKeisuke Oboki
Keisuke Oboki
CHChizuko Hirama
Chizuko Hirama
KOKazuteru Ohashi
Kazuteru Ohashi

23 July 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DSDaichi Sadato
Daichi Sadato
CHChizuko Hirama
Chizuko Hirama
AKAi Kaiho-Soma
Ai Kaiho-Soma
AYAyaka Yamaguchi
Ayaka Yamaguchi
HKHiroko Kogure
Hiroko Kogure
YHYuka Harada
Yuka Harada
Gene abnormalities, including mutations and fusions, are important determinants in the molecular diagnosis of myeloid neoplasms. The use of bone marrow (BM) smears as a source of DNA and RNA for next-generation sequencing (NGS) enables molecular diagnosis to be done with small amounts of bone marrow and is especially useful for patients without stocked cells, DNA or RNA. The present study aimed to analyze the quality of DNA and RNA derived from smear samples and the utility of NGS for diagnosing myeloid neoplasms. Targeted DNA sequencing using paired BM cells and smears yielded sequencing data of adequate quality for variant calling. The detected variants were analyzed using the bioinformatics approach to detect mutations reliably and increase sensitivity. Noise deriving from variants with extremely low variant allele frequency (VAF) was detected in smear sample data and removed by filtering. Consequently, various driver gene mutations were detected across a wide range of allele frequencies in patients with myeloid neoplasms. Moreover, targeted RNA sequencing successfully detected fusion genes using smear-derived, very low-quality RNA, even in a patient with a normal karyotype. These findings demonstrated that smear samples can be used for clinical molecular diagnosis with adequate noise-reduction methods even if the DNA and RNA quality is inferior.

12 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YHYoshihiro Hayashi
Yoshihiro Hayashi
YKYasushige Kamimura-Aoyagi
Yasushige Kamimura-Aoyagi
SNSayuri Nishikawa
Sayuri Nishikawa
RNRena Noka
Rena Noka
RIRika Iwata
Rika Iwata
HHHironori Harada
Hironori Harada
Most patients with advanced cancer develop cachexia, a multifactorial syndrome characterized by progressive skeletal muscle wasting. Despite its catastrophic impact on survival, the critical mediators responsible for cancer cachexia development remain poorly defined. Here, we show that a distinct subset of neutrophil-like monocytes, which we term cachexia-inducible monocytes (CiMs), emerges in the advanced cancer milieu and promotes skeletal muscle loss. Unbiased transcriptome analysis reveals that interleukin 36 gamma (IL36G)-producing CD38+ CiMs are induced in chronic monocytic blood cancer characterized by prominent cachexia. Notably, the emergence of CiMs and the activation of CiM-related gene signatures in monocytes are confirmed in various advanced solid cancers. Stimuli of toll-like receptor 4 signaling are responsible for the induction of CiMs. Genetic inhibition of IL36G-mediated signaling attenuates skeletal muscle loss and rescues cachexia phenotypes in advanced cancer models. These findings indicate that the IL36G-producing subset of neutrophil-like monocytes could be a potential therapeutic target in cancer cachexia.

27 July 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
HAHiroto Adachi
Hiroto Adachi
DSDaichi Sadato
Daichi Sadato
TTTakashi Toya
Takashi Toya
CHChizuko Hirama
Chizuko Hirama
KHKyoko Haraguchi
Kyoko Haraguchi
NDNoriko Doki
Noriko Doki
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.